Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyound anecdotal evidence?
Tóm tắt
Paraneoplastic neurological syndromes constitute an unusual manifestation of cancer. The objective of this case report is to debate the association between rituximab therapy and Guillain-Barre syndrome. We present the case of a 57 years old patient, with diffuse large-B cell lymphoma in complete remission, who consulted our hospital because of symmetric lower extremity weakness, developed while being treated with a rituximab maintenance schedule. Our main conclusion is that plasma cell dysregulation due to rituximab should be clarified in future studies.
Tài liệu tham khảo
Vedeler CA. Inflammatory neuropathy: update. Curr Opin Neurol. 2000;13:305–9.
Asbury A, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine. 1969;48:173–215.
Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guilain-Barre syndrome: clinical associations and outcome. Ann Neurol. 1998;44: 780–8.
Hafer-Macko C, Hsieh ST, Li GY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996;40:655–44.
Winer JB, Kangro RA, Anderson MJ, Jones DM, Kangro H, Watkins RP. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry. 1988;51:613–8.
Hahn AF. Guillatin-Barre syndrome. Lancet. 1998;352(9128):635–41.
Waksman, BH, Adams RD. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med. 1955;102:213.
Vigliani MC, Magistrello M, Polo P, Mutani R, Chio A. Risk of cancer in patients with Guillain-Barre syndrome (GBS). A population-based study. Piemonte and Valle d'Aosta Register for Guillain-Barre Syndrome. J Neurol. 2004;25(3): 321–6.
Zuk E, Nowacki P, Fabian A. Guillain-Barre syndrome in patient with Burkitt's lymphoma and type 2 diabetes mellitus. Folia Neuropathol. 2001;39(4):281–4.
Toren A, Mandel M, Shahar E, Rimmoni E. Primary central newrvous system Burkitt's lymphoma presenting as Guillain-Barre syndrome. Med Pediatr Oncol. 1994; 25(4):372–5.
Phan TG, Manoharan A, Pryor D. Relapse of central nervous system Burkitt's lymphoma presenting as Guillain-Barre syndrome and syndrome of inappropriate ADH secretion. Aust N Z J Med. 1998;28 (2):223–4.
Magne N, Foa C, Castadot P, Ott J. Guillain-Barre syndrome and non-Hodgkin's lymphoma. Report of one case and review of literature. Rev Med Brux. 2005;26 (2):108–11.
Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barre syndrome in South East England. J Neurol Neurosurg Psychiatry. 1998;64:74–7.
Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain. 2003;126(Pt 10): 2220–34.
Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol. 2002; 51(6):673–80.
Kuwabara S. Guillain-Barre syndrome: epidemiology, pathophysiology and management. Drugs. 2004;64:597–610.
Radhakrishnan VV, Sumi MG, Reuben S, Mathai A, Nair MD. Serum tumour necrosis factor-alpha and soluble tumour necrossi factor receptors levels in patients with Guillain-Barre syndrome. Acta Neurol Scand. 2004;109:71–4.
Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2++ conductance found constitutively in B-lymphocytes. J Cell Biol. 1993;121:1121–32.
Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology. 1999;52:1701–4.
Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse/human monoclonal antibody to CD20. Blood 1994;83:435–45.
Finsterer J. Treatment of immune-mediated, dysimmune neuropathies. Acta Neurol Scand. 2005;112(2):115–25.
Lunenmann JD, Prass K, Zschenderlein R. Immunotherapy of chronic inflammatory demyelinating polyneuropathy. Fortschr Neurol Psychiatr. 2004;72:672–8.
Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology. 2004;63:2178–9.
Alwayn IP, Xu Y, Basker M, et al. Effects of specific anti-B and/or anti-plasma cell immunogherapy on antibody production in baboons: depletion of CD20- and CD22- positive B cells does not result in significantly decreased production of anti-alphaGal antibody. Xenotransplantation. 2001;8:157–71.
Rojas-García R, Gallardo E, de Andrés I, de Luna N, Juárez C, Sanchez P, Illa I. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology. 2003;61 (12):1814–6.
Ghobrial IM, Fonseca R, Greipp PR, et al. Eastern Cooperative Oncology Group: Initial immunoglobulin M „flare” after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia-An Eastern Cooperative Oncology Group study. Cancer. 2004:101:2593–8.
Vanita Noronha, Thomas M. Fynan, Thomas Duffy. Flare in Neuropathy Following Rituximab Therapy for Waldenstrom's Macroglobulinemia JCO. 2006:e3.
Buda-Okreglak EM, Drabick JJ, Delaney NR. Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab. Ann Hematol. 2004; 83:117–9.